Company Press Releases Back
CytoSorbents to Present at Frankfurt MedTech Investor Forum
Tuesday May 8, 2012
MONMOUTH JUNCTION, NJ--(Marketwire -05/08/12)- CytoSorbents Corporation (OTC.BB: CTSO), a critical care-focused company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses today announced that Dr. Phillip Chan, Chief Executive Officer, will present at the Frankfurt MedTech Investor Forum on Tuesday, May 15, 2012 at the offices of Kaye Scholer LLP at Schillerstrasse 19, Frankfurt, Germany. More information can be found at www.frankfurtmedtech.de
About Frankfurt MedTech
Frankfurt MedTech (www.frankfurtmedtech.de) is a professional platform that assists many different collaborators in the life science, biotech, device and pharma industries to have successful outcomes. This unique program not only brings together companies and investors, but all people that are involved in the industry, including reporters, scientists, academia, trade organizations and international partners among others. In close co-operation with its "sister platform," the NYC MedTech Forum (www.nycmedtech.com), the meeting is especially focused on showcasing interesting US and German companies in the life sciences industries. The program provides participants with relevant and timely introductions whether through the website, email or personally at the Frankfurt MedTech Forum.
About CytoSorbents, CytoSorb®, and HemoDefend
CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption. In March 2011, CytoSorb®, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, and can now be sold throughout the European Union (E.U.) under the CE Mark to be used in clinical situations where cytokines are elevated. The goal of CytoSorb® is to modulate the immune system by removing excessive cytokines, often called "cytokine storm," in critically-ill patients that can lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death in common illnesses such as sepsis, trauma, burn injury, acute respiratory distress syndrome, and pancreatitis. CytoSorb® has demonstrated statistically significant reductions in mortality in septic patients at high risk of death and is now available for sale in Germany for the treatment of critical care illnesses under a controlled market release, with a planned broad product launch in Germany anticipated for the first half of 2012 and availability in other E.U. countries, assuming adequate and timely funding, and continued positive results from our clinical studies. HemoDefend is a development-stage blood purification technology platform for the blood transfusion industry intended to reduce transfusion reactions and safeguard the quality and safety of blood products. The HemoDefend technology utilizes the Company's polymer bead technology to remove many substances, such as antibodies, free hemoglobin and inflammatory mediators that can cause potentially serious and sometimes fatal transfusion reactions. CytoSorb® and HemoDefend are just two of a number of different polymers the Company has designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy drugs during treatment of cancer with high dose regional chemotherapy, drug detoxification, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com.
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and additional CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate and timely financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Form 10-K filed with the SEC on March 30, 2012, which is available at http://www.sec.gov.
Chief Financial Officer
(732) 329-8885 ext. *816
Source: CytoSorbents Corporation